

ICMJE DISCLOSURE FORM

Date: 13/12/2022

Your Name: Professor Stephen Johnston

Manuscript Title: Adjuvant CDK4/6 inhibitors: Can they improve clinical outcomes in hormone receptor positive early breast cancer

Manuscript number (if known): _____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	____ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genetech	Research funding to institute for laboratory studies and clinical trials
3	Royalties or licenses	____ None	

4	Consulting fees	Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, Sanofi Genzyme	Consulting or advisory role
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Pfizer, Eisai, AstraZeneca, Roche/Genetech	Speaker's bureau
6	Payment for expert testimony	___ None	
7	Support for attending meetings and/or travel	___ None	
8	Patents planned, issued or pending	___ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	___ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	___ None	
11	Stock or stock options	___ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	___ None	
13	Other financial or non-financial interests	___ None	

Please summarize the above conflict of interest in the following box:

The author reports that he receives research funding to institute for laboratory studies and clinical trials from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genetech; takes consulting or advisory role in Eli Lilly, AstraZeneca, Puma Biotechnology, Pfizer, Novartis, Sanofi Genzyme; and receives payment for Speaker's bureau from Pfizer, Eisai, AstraZeneca, Roche/Genetech.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.